(5alpha)-4,5-环氧-3,14-二羟基-17-甲基-吗喃-6,10-二酮 | 96445-15-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 中文名称: (5alpha)-4,5-环氧-3,14-二羟基-17-甲基-吗喃-6,10-二酮
• 英文名称: 10-Keto-oxymorphone
• 英文别名: 10-ketooxymorphone；Morphinan-6,10-dione, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)-；(4S,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-1,2,4,5,6,7a-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,13-dione
• CAS: 96445-15-7
• 化学式: C₁₇H₁₇NO₅
• 分子量: 315.326
• InChiKey: NKNGMQYKBKVDKI-LTIDMASMSA-N

物化性质

• 沸点：
  602.0±55.0 °C(Predicted)
• 密度：
  1.59±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  23
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  87.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  羟可待酮 在 3,5-二甲基吡唑 、 chromium(VI) oxide 、 三溴化硼 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 反应 47.0h， 生成 (5alpha)-4,5-环氧-3,14-二羟基-17-甲基-吗喃-6,10-二酮
  参考文献：
  名称：

  10-Ketonaltrexone and 10-ketooxymorphone

  摘要：

  Ethylketocyclazocine (1) has greater kappa/mu selectivity than cyclazocine in brain binding assays. 10-Ketonaltrexone (11) and 10-ketooxymorphone (10) were prepared from naltrexone 3-methyl ether and oxycodone, respectively. Bioassays in the myenteric plexus longitudinal muscle preparation of the guinea pig ileum and in the mouse vas deferens, in addition to brain binding assays, demonstrated that 10 and 11 were far less potent than naltrexone (2) and oxymorphone (3) at mu sites and also had little affinity for kappa and delta sites. It is concluded that introduction of the 10-keto group in naltrexone and oxymorphone diminished opioid effects at all binding sites.

  DOI：

  10.1021/jm00145a024

文献信息

• [EN] PROCESS FOR IMPROVED OPIOID SYNTHESIS<br/>[FR] PROCÉDÉ POUR AMÉLIORER LA SYNTHÈSE D'OPIOÏDES
  申请人：RHODES TECHNOLOGIES

  公开号：WO2014013311A1

  公开（公告）日：2014-01-23

  Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxycodone base and/or an oxycodone salt; processes for preparing these compounds and compositions; uses of these compounds and compositions in the preparation of APIs and pharmaceutical dosage forms; and uses of said APIs and pharmaceutical dosage forms in the treatment of medical conditions.

  用于制备阿片类药物的起始物或中间物的化合物和组合物，例如，羟考酮基和/或羟考酮盐；制备这些化合物和组合物的过程；这些化合物和组合物在制备活性药物成分和制药剂量形式中的用途；以及这些活性药物成分和制药剂量形式在治疗医疗状况中的用途。
• [EN] REDUCTION OF ALPHA, BETA-UNSATURATED KETONE LEVELS IN MORPHINAN DERIVATIVE COMPOSITIONS<br/>[FR] RÉDUCTION DES NIVEAUX DE CÉTONE ALPHA, BETA-INSATURÉE DANS DES COMPOSITIONS DE DÉRIVÉS DE MORPHINANE
  申请人：RHODES TECHNOLOGIES

  公开号：WO2016005923A1

  公开（公告）日：2016-01-14

  The disclosure relates to processes for reducing the amount of a compound of formula (I) or a salt or a solvate thereof present in a composition comprising compounds of formulae (I) and (II) or a salt or a solvate thereof.

  本公开涉及减少式(I)化合物或其盐或溶剂合物在包含式(I)和(II)化合物或其盐或溶剂合物的组合物中的数量的方法。
• PROCESS FOR IMPROVED OXYMORPHONE SYNTHESIS
  申请人：RHODES TECHNOLOGIES

  公开号：US20170022209A1

  公开（公告）日：2017-01-26

  Processes for preparing oxymorphone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxymorphinone salt in the presence of trifluoroacetic acid and/or a glycol.

  提供制备氧吗啡的工艺。该工艺包括一步，在三氟乙酸和/或一种二元醇的存在下对14-羟基吗啡酮盐进行氢化的步骤。
• [EN] PROCESS FOR IMPROVED OPIOID SYNTHESIS<br/>[FR] PROCÉDÉ POUR LA SYNTHÈSE AMÉLIORÉE D'OPIOÏDES
  申请人：RHODES TECHNOLOGIES

  公开号：WO2014013313A1

  公开（公告）日：2014-01-23

  Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxymorphone base and/or an oxymorphone salt; processes for preparing these compounds and compositions; uses of these compounds and compositions in the preparation of APIs and pharmaceutical dosage forms; and uses of said APIs and pharmaceutical dosage forms in the treatment of medical conditions.

  用作制备阿片类药物的起始物质或中间物质的化合物和组合物，例如氧吗啡基和/或氧吗啡盐; 制备这些化合物和组合物的过程; 在制备API和制药剂量形式中使用这些化合物和组合物的用途; 以及在治疗医疗状况中使用所述API和制药剂量形式的用途。
• Process for improved oxymorphone synthesis
  申请人：RHODES TECHNOLOGIES

  公开号：US10189852B2

  公开（公告）日：2019-01-29

  Processes for preparing oxymorphone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxymorphinone salt in the presence of trifluoroacetic acid and/or a glycol.

  提供了制备羟吗啡酮的工艺。所述工艺包括一个步骤，即在三氟乙酸和/或乙二醇存在下对 14-羟基吗啡酮盐进行氢化。